中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2009年
6期
3-6
,共4页
邓英辉%吴靖林%付文静%贾强
鄧英輝%吳靖林%付文靜%賈彊
산영휘%오정림%부문정%가강
肾透析%钙%磷%生活质量
腎透析%鈣%燐%生活質量
신투석%개%린%생활질량
Renal dialysis%Calcium%Phosphorus%Quality of life
目的 改进对血液透析患者钙磷代谢异常的治疗,观察患者生活质量的改善.方法按照美国肾脏基金会(NKF)制定的"慢性肾脏病,透析病人生存质量指南(K/DOQI)"改进对血液透析患者钙磷代谢异常的治疗,观察1年后患者的血清钙、磷、钙磷乘积、全段甲状旁腺素(iPTH)等水平及治疗达标率的变化.应用肾脏病调查表(KDQ)评估患者生活质量的改善.结果改进治疗后患者的血清钙、磷、钙磷乘积及iPTH水平均较改进治疗前有明显下降(P<0.01或<0.05).改进治疗后治疗达标率分别为:血清钙74.42%(32/43)、血清磷62.79%(27/43)、钙磷乘积55.81%(24/43)、iPTH 60.47%(26/43)、四项达标25.58%(11/43),均较改进治疗前有明显上升(P<0.01或<0.05).改进治疗后KDQ评分的总分及各方面得分均较改进治疗前有明显增加(P<0.01).结论改进治疗后患者钙磷代谢情况较改进治疗前改善,生活质量提高.
目的 改進對血液透析患者鈣燐代謝異常的治療,觀察患者生活質量的改善.方法按照美國腎髒基金會(NKF)製定的"慢性腎髒病,透析病人生存質量指南(K/DOQI)"改進對血液透析患者鈣燐代謝異常的治療,觀察1年後患者的血清鈣、燐、鈣燐乘積、全段甲狀徬腺素(iPTH)等水平及治療達標率的變化.應用腎髒病調查錶(KDQ)評估患者生活質量的改善.結果改進治療後患者的血清鈣、燐、鈣燐乘積及iPTH水平均較改進治療前有明顯下降(P<0.01或<0.05).改進治療後治療達標率分彆為:血清鈣74.42%(32/43)、血清燐62.79%(27/43)、鈣燐乘積55.81%(24/43)、iPTH 60.47%(26/43)、四項達標25.58%(11/43),均較改進治療前有明顯上升(P<0.01或<0.05).改進治療後KDQ評分的總分及各方麵得分均較改進治療前有明顯增加(P<0.01).結論改進治療後患者鈣燐代謝情況較改進治療前改善,生活質量提高.
목적 개진대혈액투석환자개린대사이상적치료,관찰환자생활질량적개선.방법안조미국신장기금회(NKF)제정적"만성신장병,투석병인생존질량지남(K/DOQI)"개진대혈액투석환자개린대사이상적치료,관찰1년후환자적혈청개、린、개린승적、전단갑상방선소(iPTH)등수평급치료체표솔적변화.응용신장병조사표(KDQ)평고환자생활질량적개선.결과개진치료후환자적혈청개、린、개린승적급iPTH수평균교개진치료전유명현하강(P<0.01혹<0.05).개진치료후치료체표솔분별위:혈청개74.42%(32/43)、혈청린62.79%(27/43)、개린승적55.81%(24/43)、iPTH 60.47%(26/43)、사항체표25.58%(11/43),균교개진치료전유명현상승(P<0.01혹<0.05).개진치료후KDQ평분적총분급각방면득분균교개진치료전유명현증가(P<0.01).결론개진치료후환자개린대사정황교개진치료전개선,생활질량제고.
Objective To improve the treatment of abnormal calcium-phosphorus metabolism in hemodialysis patients, and observe its influence on the quality of life. Methods Implemented the kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines for bone metabolism and disease in hemodialysis patients, improved the treatment of abnormal calcium-phesphoms metabolism in hemodialysis patients. After 1 year, the values were compared between before and after application of K/DOQI guidelines, including albumin-adjusted serum calcium, phosphorus, calcium × phosphorus (Ca × P) product, and intact parathyroid hormone (iPTH) and their achieved target range rates. The quality of life were evaluated by using the kidney disease questionnaire (KDQ). Results One year later, the levels of serum calcium, phosphorus, Ca × P product, and iPTH were all decreased (P<0.01 or <0.05) compared with before the application of K/DOQI guidelines. The percentage of patients fell within the guideline range were as follows: 74.42% (32/43), calcium; 62.79%(27/43), phosphorus; 55.81%(24/43), Ca × P product; 60.47%(26/43), iPTH; 25.58%(11/43), all four criteria, higher than before (P<0.01 or <0.05). The scores of KDQ in global indices and symptom scores of physical symptoms, fatigue, depression, relationships with others and frustration dimension were also all increased (P<0.01). Conclusion The state of calcium-phospberns metabolism in hemodialysis patients is improved, the quality of life is also enhanced.